A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The primary purpose of this study is to compare the progression-free survival (PFS) of participants with radioiodine (131 I)-refractory differentiated thyroid cancer (DTC) and radiographic evidence of disease progression within the prior 12 months treated with lenvatinib 24 mg by continuous once daily (QD) oral dosing versus placebo.
Epistemonikos ID: aefc768931197f1629dd10d44657a77d38897ae6
First added on: May 26, 2022